common.study.topics.clinical

TUDCA as a Therapy for Ulcerative Colitis (UC)

common.study.values.description

“TUDCA as a Therapy for Ulcerative Colitis (UC)”

This is a Phase I open label study examining the efficacy and safety of TUDCA (tauroursodeoxycholic acid) in ulcerative colitis treatment.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Tauroursoursodeoxycholic acid, brand name Tudcabil

Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase I Open Label Study of the Efficacy and Safety of Tudca in Ulcerative Colitis

common.study.values.clinical-trial-id

NCT04114292

participant.views.study.view.id

erk3Ea